Pharmac

• Regardless of the election result, a form of austerity was always going to win.
• While National and Labour both offered targeted support for those struggling to get by, such as tax cuts (National) or the removal of GST from fruit and vegetables (Labour), such mitigation seems paltry by comparison.

Radical incrementalism?

• Many contend Labour has abandoned the free-market fundamentalism associated with “Rogernomics” that it adopted in the 1980s.
• Under the Labour governments led by Jacinda Ardern and then Chris Hipkins, there was an attempt to ameliorate the worst excesses of market capitalism.
• Hipkins, for instance, insisted Labour’s policies were not simply about “tinkering around the edges of the neoliberal model”.

The ‘third way’

• A rough scholarly consensus has emerged that neoliberalism has shown a remarkable ability to evolve.
• Labour – and to some extent National – have rejected the harsh “vanguard neoliberalism” of the 1980s and ‘90s.
• For example, the Labour government’s COVID business support and wage subsidy scheme was supposedly undertaken to protect workers from unemployment.
• Read more:
  With ACT and NZ First promising to overhaul Pharmac, what’s in store for publicly funded medicines?

Intervention for the market

• In this sense, the various palliative reforms made by the Ardern-Hipkins governments do not represent a fundamental swing away from neoliberalism.
• She said Labour accepted the need for government intervention in the market.
• Rather, at its core, it is about imposing a global and state framework that favours business and private property.

The underlying consensus

• National is more business-friendly and seems poised to make deeper cuts to public services.
• To differing degrees, National and its probable coalition partner ACT reject the “progressive” aspects of what feminist scholar Nancy Fraser called “progressive neoliberalism”.
• But beneath those apparent ideological differences there remains an underlying neoliberal consensus.
• This is especially so with the election success of parties promising to reduce government spending.

• TORONTO, July 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the Company or Acerus) (TSX:ASP, OTCQB:ASPCF) today announced that, on June 15, 2021, it prevailed at a preliminary issue trial in which Recipharm Limited (Recipharm) alleged that Acerus claim for damages was barred by the terms of the companies manufacturing contract.
• "This is an important step forward in Acerus effort to hold Recipharm accountable for its contractual breaches, said Ed Gudaitis, President and Chief Executive Officer of Acerus.
• Manufacturers in the pharmaceutical industry rely on contract manufacturing organizations like Recipharm to ensure that patients have access to the medicines they need.
• On June 18, 2020, Acerus announced it had commenced litigation against Recipharm, a wholly-owned subsidiary of Recipharm AB, in the Commercial Court of London.

• It is mandatory for pharmaceuticals companies developing new medicines to follow the standards of security and privacy.
• Cloud signing solutions help pharmaceuticals companies save substantially on shipping charges and accelerate time to market and development of new drugs.
• The European market for hardware security modules has been segmented into Germany, the UK, France, Italy, the Netherlands, and the Rest of Europe.
• Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM".

• LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. to its Board of Directors, effective June 4, 2021.
• Dr. Lindborgs appointment fills the vacancy created by Dr. Alberto Martinez upon his retirement from Celsions Board on December 31, 2020.
• Dr. Lindborg brings to Celsion more than 25 years of pharmaceutical industry experience with a particular focus on R&D, executive management and strategy.
• Were proud to welcome an accomplished scientist, thought and business leader of Dr. Lindborgs caliber to the Celsion Board of Directors, said Michael H. Tardugno, Celsion Corporations chairman, president and chief executive office.